



# PRIX GALIEN USA

THE GALEN PRIZE

## Charter of the Prix Galien USA Committee

The pharmaceutical and biotechnology products to be considered in the Prix Galien USA shall have been based on innovative science, developed by synthetic chemistry or molecular biology, manufactured to precise specifications, tested in controlled clinical trials and marketed by ethical pharmaceutical, biotechnology, and medical device companies. The committee will follow a century-old example set in Sweden. The Prix Nobel rewards excellence and novelty, and awards special honors to those who have served humanity at large.

As to the Science: just as winners in Stockholm are chosen from nominations in such fields as physiology, immunology, biochemistry, neurobiology, etc. -- and each is judged against all of the others -- so our awardees will be chosen from among therapeutic categories such as: autoimmune diseases, infectious diseases, orphan drugs, oncology, congenital and musculoskeletal diseases, respiratory diseases, cardiovascular diseases, etc.

We will judge which among the candidates, independent of any category, is the Best Pharmaceutical Agent (i.e. small molecule), which is the Best Biotechnology Product, and which is the Best Medical Device approved in the USA in the past ten years. As few as one or as many as three prizes may be awarded in each of these categories, and from time to time the committee may decide on awards *hors prix*.

The prizes are awarded for pharmaceutical science that improves the human condition. We base our selection on only two criteria. We will ask:

One: What was innovative in the course of its scientific development, application or clinical utility?

Two: Was its discovery heuristic? Did we learn anything for the future of biomedical science from its introduction to the clinic?

Criteria that will *not* be considered will be the size of the market, the size of the company, the cost of development or the contingencies of distribution.

In addition, at the discretion of the committee, The Prix Galien USA will award a special Pro Bono Humanum award to an individual, a company, an academic institution, or a non-governmental agency that has helped to improve the human condition through the application of pharmaceutical science to problems of developing or underserved populations worldwide.